Gufic Biosciences Analyst Review May 2026
- May 21, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Gufic Biosciences analyst review for May 2026 covers the key data investors need for GUFICBIO at its current price of Rs 395. Gufic Biosciences (NSE: GUFICBIO) is a specialty pharmaceutical company with a market capitalisation of approximately Rs 2,200 crore, focusing on lyophilised injectables and critical care products. The analyst consensus target of Rs 480 implies meaningful upside, and this Gufic Biosciences analyst review examines technical levels, business performance, valuation, and key risks for GUFICBIO through FY27.
Click Here – Get Free Investment Predictions
Gufic Biosciences Company Snapshot May 2026
Gufic Biosciences’ lyophilised injectable manufacturing capability (complex freeze-dried drugs) is rare and high-barrier. Critical care products (antifungals, anti-infectives) sold in hospitals across India generate recurring institutional revenue. The table below summarises the key data referenced in this Gufic Biosciences analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | GUFICBIO |
| Sector | Pharmaceuticals – Injectables and Lyophilisation |
| CMP (May 2026) | Rs 395 |
| 52 Week High | Rs 540 |
| 52 Week Low | Rs 340 |
| Market Cap | Rs 2,200 Crore |
| Trailing P/E | 30x |
| Analyst Consensus Target | Rs 480 |
| Bull Case Target | Rs 580 |
| Bear Case Target | Rs 320 |
Analyst Insight in This Gufic Biosciences Analyst Review
Senior Research Analyst Ankit Jaiswal flags Gufic Biosciences as a stock to watch in May 2026. At Rs 395, Ankit Jaiswal identifies key support in the Rs 347 to Rs 375 band and resistance near Rs 419. He suggests watching Gufic Biosciences for a potential move toward Rs 480, subject to Pharmaceuticals – Injectables and Lyophilisation sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Gufic Biosciences analyst review and does not constitute a trade recommendation.
Technical Analysis in This Gufic Biosciences Analyst Review
At Rs 395, GUFICBIO is trading within its 52-week band of Rs 340 to Rs 540. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 347 to Rs 375 band while resistance is seen in the Rs 419 to Rs 438 zone. A sustained move above Rs 419 could open the path toward the analyst consensus target of Rs 480 as identified in this Gufic Biosciences analyst review.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 347 to Rs 375 – investors tracking this Gufic Biosciences analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for GUFICBIO.
- Resistance Zone: Rs 419 to Rs 438 – a sustained close above Rs 419 would be a positive breakout signal worth flagging in this Gufic Biosciences analyst review.
- Medium-Term Target: The analyst consensus of Rs 480 represents the base-case upside scenario in this Gufic Biosciences analyst review.
Business Segment Analysis
Lyophilised Injectable Manufacturing (Core Technology)
This is the primary revenue and margin driver for Gufic Biosciences, directly supporting the earnings trajectory toward the consensus target of Rs 480.
Critical Care Antifungal and Anti-infective Drugs
This segment adds scale and diversification to Gufic Biosciences’s business model and is a meaningful EPS contributor through FY27 and FY28.
Hospital and Institutional Sales Channel
This represents the medium-term growth frontier for Gufic Biosciences and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Gufic Biosciences Analyst Review
At Rs 395, Gufic Biosciences trades at a trailing P/E of 30x. This Gufic Biosciences analyst review presents three scenarios: a bull case of Rs 580 on strong earnings delivery, a base case of Rs 480 at analyst consensus, and a bear case of Rs 320 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Gufic Biosciences analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 580 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 480 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 320 | Earnings miss or macro headwinds |
Trade Outlook for Gufic Biosciences
Based on the technical and fundamental analysis in this Gufic Biosciences analyst review, investors might watch GUFICBIO near the support zone of Rs 347 to Rs 375 for potential opportunities. A flag above Rs 419 could suggest improving momentum toward Rs 480. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Gufic Biosciences in FY27
A well-rounded Gufic Biosciences analyst review must assess downside risks. Key risks for Gufic Biosciences include a macro slowdown affecting Pharmaceuticals – Injectables and Lyophilisation sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in GUFICBIO.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Gufic Biosciences Analyst Review Verdict for 2026
This Gufic Biosciences analyst review concludes that at Rs 395, GUFICBIO offers a defined risk-reward with a consensus target of Rs 480. The 52-week range of Rs 340 to Rs 540 provides context on the current entry point. Use this Gufic Biosciences analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on GUFICBIO.
Frequently Asked Questions: Gufic Biosciences Analyst Review 2026
What is the analyst target for Gufic Biosciences in 2026?
The analyst consensus target is Rs 480, with a bull case of Rs 580 and a bear case of Rs 320. This Gufic Biosciences analyst review recommends monitoring Q1 FY27 earnings for confirmation.
Is Gufic Biosciences a good investment at Rs 395?
At Rs 395 with a P/E of 30x and a consensus target of Rs 480, this Gufic Biosciences analyst review is constructive for medium to long-term investors in the Pharmaceuticals – Injectables and Lyophilisation sector. Always consult a SEBI-registered advisor before investing.
What is Gufic Biosciences’s 52-week high and low?
The 52-week high is Rs 540 and the 52-week low is Rs 340. At Rs 395, GUFICBIO is positioned within this range as noted in this Gufic Biosciences analyst review.
What are the key risks for Gufic Biosciences?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – Injectables and Lyophilisation sector as assessed in this Gufic Biosciences analyst review.
Where can I track live data for Gufic Biosciences?
Track Gufic Biosciences’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Gufic Biosciences analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
